Trial Profile
A Randomized, Double Blind Study of the Safety and Efficacy of GSK1349572 50mg Once Daily to Raltegravir 400mg Twice Daily Both Administered With Fixed-dose Dual Nucleoside Reverse Transcriptase Inhibitor Therapy Over 96 Weeks in HIV-1 Infected Antiretroviral Therapy Naive Adult Subjects
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 01 Sep 2023
Price :
$35
*
At a glance
- Drugs Dolutegravir (Primary) ; Emtricitabine/tenofovir disoproxil fumarate; Lamivudine/abacavir; Raltegravir
- Indications HIV-1 infections
- Focus Registrational; Therapeutic Use
- Acronyms SPRING-2
- Sponsors ViiV Healthcare
- 08 Oct 2020 Results of pooled analysis assessing the efficacy and safety profile of the integrase strand transfer inhibitor (INSTI) dolutegravir (DTG) relative to comparator ART in PLWH naive to ART by age group from four phase III/IIIb, presented at the 15th International Congress on Drug Therapy and HIV Infection
- 22 Mar 2019 This trial has been completed in United Kingdom, according to European Clinical Trials Database.
- 22 Jul 2015 Pooled subgroup analysis, results presented at the 8th International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention.